Gambhir S S, Hoh C K, Phelps M E, Madar I, Maddahi J
Crump Institute for Biological Imaging, Department of Molecular and Medical Pharmacology, UCLA School of Medicine 90095-1770, USA.
J Nucl Med. 1996 Sep;37(9):1428-36.
Preliminary studies have shown that PET is more accurate than CT for the staging of non-small-cell lung carcinoma (NSCLC). However, the potential effect of PET on the management of these patients and its cost-effectiveness has not been rigorously studied. Thus, we have used decision tree sensitivity analysis to assess the cost-effectiveness of a PET based strategy for staging of NSCLC.
Two decision strategies for selection of potential surgical candidates were compared; thoracic CT alone or thoracic CT and thoracic PET. The first decision tree was conservatively constructed by requiring mediastinoscopy (biopsy) to confirm imaging results so that no patient with surgically curable disease would miss the opportunity for surgery in either strategy. A second less conservative tree in which only nonconcordant results are biopsied was also tested. The various paths of each strategy are dependent on numerous parameters which were determined from a review of the medical literature. Life expectancy was calculated using the declining exponential approximation of life expectancy and reduced based on procedural mortality. Costs were based on mean costs at our institution. For all possible outcomes of each strategy, the expected cost and projected life expectancy were determined. The effect of changing one or more parameters on the expected cost and life expectancy were studied using a sensitivity analysis.
The CT + PET strategy in the conservative decision tree showed a saving of $1154 per patient without a loss of life expectancy (increase of 2.96 days) as compared to the alternate strategy of CT alone. Both these effects were the result of improved staging of lung carcinoma prior to the decision for surgery. The CT + PET strategy in the less conservative decision tree showed a savings of $2267 per patient but misses 1.7% of potentially operable patients.
These results show through rigorous decision tree analysis, the potential cost-effectiveness of using FDG PET in the management of NSCLC. These results form a basis for detailed study of the results obtained from multicenter trials on the accuracy of PET in NSCLC management. Furthermore, the techniques utilized for decision tree analysis have broad range of applicability to the entire field of nuclear medicine.
初步研究表明,在非小细胞肺癌(NSCLC)分期方面,PET比CT更准确。然而,PET对这些患者治疗的潜在影响及其成本效益尚未得到严格研究。因此,我们使用决策树敏感性分析来评估基于PET的NSCLC分期策略的成本效益。
比较了两种选择潜在手术候选者的决策策略;单纯胸部CT或胸部CT与胸部PET。第一个决策树通过要求纵隔镜检查(活检)来保守构建,以确认影像学结果,这样在任何一种策略中,患有可手术治愈疾病的患者都不会错过手术机会。还测试了第二个不太保守的决策树,其中仅对不一致的结果进行活检。每种策略的各种路径取决于从医学文献回顾中确定的众多参数。使用预期寿命的递减指数近似法计算预期寿命,并根据手术死亡率进行降低。成本基于我们机构的平均成本。对于每种策略的所有可能结果,确定预期成本和预期寿命。使用敏感性分析研究改变一个或多个参数对预期成本和预期寿命的影响。
与单纯CT的替代策略相比,保守决策树中的CT + PET策略显示每位患者节省1154美元,且预期寿命没有损失(增加2.96天)。这两种效果都是由于在决定手术前肺癌分期得到改善。不太保守的决策树中的CT + PET策略显示每位患者节省2267美元,但会遗漏1.7%的潜在可手术患者。
这些结果通过严格的决策树分析表明,在NSCLC治疗中使用FDG PET具有潜在的成本效益。这些结果为详细研究NSCLC管理中PET准确性的多中心试验结果奠定了基础。此外,用于决策树分析的技术在核医学整个领域具有广泛的适用性。